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Serum Concentration of Myosin Light Chain I and Left Ventricular
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Department of Pediatrics, Faculty of Medicine, Tottori University, Yonago 683-0826, Japan
We compared the serum concentrations of myosin light chain I (MLC-I) and left ven-
tricular shortening fraction (LVSF) measured by echocardiography of 13 normal neo-
nates with those of 38 neonates with fetal distress, neonatal asphyxia, or cardiovascular/
respiratory diseases not associated with structural abnormalities.  The diseased group
included 9 neonates with elevated MLC-I concentrations and 18 with low LVSF.  Elevat-
ed MLC-I concentrations were frequently noted in neonates with transient myocardial
ischemia and persistent pulmonary hypertension of the newborn, suggesting a high
specificity of MLC-I elevation in these diseases.  Although echocardiographically deter-
mined LVSF identifies the affected sections of the myocardium, it did not allow rating
of the severity of the disorder.  There was no correlation between MLC-I and LVSF
probably due to therapeutic interventions and pulmonary hypertension.  Our results
suggest that MLC-I is a useful marker of neonatal myocardial diseases.
Key words:  acute myocardial infarction; heart failure; persistent pulmonary hypertension of the
newborn; transient myocardial ischemia of the newborn infant
Abbreviations:  AMI, acute myocardial infarction; AST, aspartate aminotransferase; CK, creatine
phosphokinase; EFE, endocardial fibroelastosis; FD, fetal distress; MAS, meconium aspiration syndrome;
MLC-I, myosin light chain I; LVSF, left ventricular shortening fraction; NA, neonatal asphyxia; PPHN,
persistent pulmonary hypertension of the newborn; RDS, respiratory distress syndrome; TMI, transient
myocardial ischemia of the newborn infant; TTN, transient tachypnea of the newborn
Myocardial myosin light chain I (MLC-I), a
component of the myocardial structural protein,
plays a key role in myocardial constriction as
well as echocardiographically left ventricular
shortening fraction (LVSF).  Previous studies
showed increased blood levels of MLC-I in
myocyte disorders, and indicated that MLC-I is
a good marker of myocardial necrosis and is
useful in the diagnosis and follow-up of myo-
cardial infarction (Trahern et al., 1978; Yazaki
et al., 1980).  In neonates, asphyxia and various
other pathologic conditions may cause heart
failure.  In this regard, MLC-I may potentially
be a useful marker for the assessment of the
severity of heart failure.  To explore the useful-
ness of MLC-I for this purpose in the pediatric
population, we compared the LVSF, determin-
ed by echocardiography, with serum concen-
trations of MLC-I, as an index of myocardial
ischemia and myocyte necrosis, in neonates
with fetal distress, neonatal asphyxia, and those
with circulatory/respiratory diseases not associ-
ated with cardiac structural abnormalities, and
compared these parameters with those of nor-
mal neonates.
Subjects and Methods
Subjects
We studied 13 newborn children with no physi-
cal abnormalities weighing more than 2,500 g
who were delivered normally at full-term at our
hospital (normal neonates).  The group consist-
ed of 9 boys and 4 girls, with a mean gestational
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period and mean birth weight of 38 weeks and 6
days (range: 37 weeks and 0 day–40 weeks and
6 days) and 2,986 g (range: 2,500–3,392 g), res-
pectively.  We also examined 38 newborns at
our hospital or affiliated facilities, with a his-
tory of fetal distress (FD), neonatal asphyxia
(NA), or circulatory/respiratory diseases not
associated with anatomical abnormalities.  We
defined all cases using the biophysical profile
score (Manning et al., 1985) with less than 6
points as FD.  The group consisted of 27 boys
and 11 girls, with a mean gestational period and
mean birth weight of 34 weeks and 1 day (range:
27 weeks and 4 days–42 weeks and 2 days) and
2,107 g (range: 782–3,504 g), respectively.  The
diseased group consisted of the following:  i)
The FD group comprised 6 patients, including 5
with complications—2 with transient tachypnea
of the newborn (TTN), 1 with meconium aspir-
ation syndrome (MAS) and 2 with transient
myocardial ischemia of the newborn infant
(TMI); ii) The FD + NA group consisted of 12
patients, including 7 with complications—2
with respiratory distress syndrome (RDS), 4
with TMI and 1 with MAS/persistent pulmo-
nary hypertension of the newborn (PPHN); iii)
The NA group consisted of 9 patients, including
8 with complications—2 with TTN, 3 with RDS
and 3 with TMI; iv) The remaining newborns
had the following underlying diseases—TTN in
4 patients, PPHN with TTN in 1, RDS in 2, TMI
in 1, left ventricular dilation disease similar to
endocardial fibroelastosis (EFE-like disease) in
1, shock caused by anencephaly in 1, and latent
FD with reduced LVSF without heart failure in
1.  Severe NA, defined by a 1-min Apgar score
of 0 to 4 points, was noted in 13 patients.  Of the
circulatory/respiratory diseases there was TTN
in 9 patients, RDS in 7, MAS in 2, PPHN in 2,
and TMI in 10.  There were 3 infants in 2 pairs,
all with twin-to-twin transfusion syndrome
(Table 1).  Definite criteria are available for the
diagnosis of TMI and PPHN; these 2 are often
viewed together as one pathological condition
(Riemenschneider et al., 1976; Levin et al.,
1979).  The diagnosis of PPHN was established
in patients with marked pulmonary hyperten-
sion irrespective of the cause and the remaining
fetal circulation, and TMI in patients with heart
failure symptoms, and without underlying
respiratory diseases, congenital heart diseases
or metabolic diseases (Rowe, 1977; Daga et al.,
1983).
Methods
Measurement of MLC-I
Serum concentrations of MLC-I were mea-
sured using the Yamaha EIA myosin L-1 kit
(Yamasa Shoyu Co., Choshi, Japan).  Briefly,
the inner walls of a tube were first coated with
an anti-human ventricular myocardial MLC-I
mouse antibody (MLM-544; solid phase anti-
body, Yamasa Shoyu).  To this tube, we added
200 m L of a peroxidase-labeled anti-human
ventricular myocardial MLC-I mouse antibody
(MLM-508; enzyme antibody, Yamasa Shoyu),
and a 50- m L sample (antigen), followed by inc-
ubation for 1 h.  After triplicate washing with
2,000 m L of 0.9% NaCl, we added 500 m L of a
color-developing substrate (liquid A: tetra-
methylbenzidine; liquid B: hydrogen peroxide),
followed by incubation at 15 to 30˚C for 30
min.  Finally, 1,000 m L of a reaction stopper (2
N H2SO4) was added and mixed, followed by
determination of absorbance at a 450 nm wave-
length using a spectrophotometer.  Serum con-
centrations of MLC-I were determined by a
working curve constructed using the kit com-
ponent standard myosin solution.
Determination of LVSF
All ultrasonographic studies were perform-
ed by the same operator with an SSD-875
(Aloka, Tokyo, Japan) with a 5.0 MHz trans-
ducer.  Left ventricular internal dimensions at
end-diastole and -systole were measured by a
thoracic near-sternal procedure using the meth-
od of Sahn and coworkers (1978) , while the
child was in a supine position.  Data from 3 runs
obtained on recording paper were averaged.
LVSF was then calculated using the following
equation:
LVSF = (LVIDd - LVIDs) / LVIDd
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Fig. 1.  Comparison of MLC-I between normal and diseased
groups.  *Groups have duplicate cases.   E, MLC-I < 1.0 ng/mL; J,
MLC-I ‡  1.0 ng/mL.  A significant difference is noted between the
normal and TMI groups.  No significant difference in MLC-I is not-
ed in the FD, NA and FD + NA groups compared with the normal
group.  [  ], patient number of the group.  FD, fetal distress; MLC-I,
myosin light chain I; NA, neonatal asphyxia; NS, not significant;
TMI, transient myocardial ischemia of the newborn infant.
where LVIDd = left ventricular
internal dimension at end-
diastole, LVIDs = left ventric-
ular internal dimension at end-
systole.
Protocol
In the normal neonates, a 1-mL
blood sample was collected from
the dorsal vein of the hand on
day 2 (3rd day of life) and used
for the determination of MLC-I.
In addition, we also determined
LVSF on day 0 (1st day of life).
Both procedures were repeated
on day 5.  In the diseased group,
a 1-mL blood sample was
collected from the dorsal vein of
the hand or radial artery and
assayed for MLC-I during
hospitalization (within 24 h after
delivery).  We also determined
LVSF at the same time.  In 25 of
the 38 patients, MLC-I and
LVSF were also determined on
days 2 through 10, more specifically in 6 pa-
tients on days 0 and 2, in 3 on days 0 and 3, in 2
on days 0 and 5, in 3 on days 0 and 6, in 7 on
days 0 and 10, in 2 on days 0, 2 and 6, and in 2
on days 0, 5 and 8 (Table 1).  In addition, pa-
tients with reduced LVSF were also examined
over several days.
Statistical analysis
Data were expressed as the mean –  SD.  Dif-
ferences between groups were examined for
statistical significance by Mann-Whitney’s U-
test.  A P value of less than 0.05 denoted the
presence of a significant difference.
Results
MLC-I in normal neonates
In 12 of the 13 normal neonates, blood MLC-I
concentrations were below the detection limit
(< 1.0 ng/mL).  However, in 1 neonate, a con-
centration of 3.1 ng/mL was noted on day 2.  On
day 5, the concentrations were below the
detection limit in all 13 neonates.  There was no
significant difference in MLC-I between days 2
and 5.
MLC-I in the diseased group
Of the 38 patients, nine had elevated MLC-I
concentrations, on day 0 in 8 and on day 2 in 1
(1.2–10 ng/mL).  Of these, 8 had FD or NA,
including 7 with TMI and 1 with MAS and
PPHN.  The remaining patient had shock
caused by anencephaly.  Thus, MLC-I was not
elevated in patients with FD or NA who did not
have associated TMI or PPHN.  MLC-I was
also not elevated in patients with circulatory/
respiratory diseases not associated with FD or
NA.  The mean concentration of MLC- I in the
TMI group was significantly higher than in the
normal group (P < 0.05).  But the mean concen-
trations in FD, NA and FD + NA groups were
M
LC
-I
Normal TMI* FD* NA* FD+NA*
   [13] [10] [18] [21] [12]
(ng/mL)
10
5
P < 0.05
NS
NS
NS
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Table 1.  Patient data
  Pa- Sex Disease Gestational Body Apgar MLC-I LVSF
 tient  age weight score (ng/mL) (%)
number (wk and d) (g) (1/5 min) [Age in d] [Age in d]
  1 M FD 37 wk 6 d 2529 7/  9 <1   [0] fi  <1 [  6] 38 [0] fi  32 [6]
  2 M FD, TTN 35 wk 3 d 1241 9/10 <1   [0] 38 [0]
  3 M FD, TTN 34 wk 0 d 1866 9/  9 <1   [0] 30 [0]
  4 M FD, MAS 40 wk 6 d 2308 8/  9 <1   [0] 33 [0]
  5 M FD, TMI 37 wk 0 d 2674 8/  8   5.0[0] fi  <1 [10] 15 [0] fi  28 [10]
  6 F FD, TMI 32 wk 3 d 2144 9/  9   1.9[0] fi  <1 [10] 11 [0] fi  31 [10]
  7 F FD, NA 28 wk 3 d 995 1/  4 <1   [0] fi  <1 [  6] 30 [0] fi  32 [  6]
  8 F FD, NA 40 wk 2 d 3504 6/  9 <1   [0] fi  <1 [  3] 33 [0] fi  34 [  3]
  9 M FD, NA 39 wk 1 d 2928 4/  9 <1   [0] 28 [0]
10 F FD, NA 38 wk 6 d 2530 2/  5 <1   [0] fi  <1 [  2] 21 [0] fi  38 [  2]
11 M FD, NA 29 wk 3 d 782 3/  8 <1   [0] 27 [0]
12 F FD, NA, RDS 31 wk 3 d 1942 3/  7 <1   [0] fi  <1 [  5] 24 [0] fi  29 [  5]
13 M FD, NA, RDS 29 wk 4 d 1412 5/  5 <1   [0] fi  <1 [  2] 23 [0] fi  30 [  2]
14† M FD, NA, TMI 40 wk 2 d 3176 0/  0   5.3[0] 20 [0]
15 F FD, NA, TMI 31 wk 4 d 1974 1/  6 <1   [0] fi  <1 [10]   6 [0] fi  25 [10]
16 M FD, NA, TMI 39 wk 3 d 3330 6/  8   3.1[0] fi  <1 [10] 20 [0] fi  32 [10]
17 M FD, NA, TMI 32 wk 0 d 1836 1/  2   1.2[0] fi  <1 [10] 24 [0] fi  30 [10]
18 M FD, NA, MAS/
PPHN 42 wk 2 d 3312 5/  3 <6.3[0] fi    7.4[2] 38 [0] fi  32 [  2]
                fi  3.7[6]               fi  34 [6]
19 F NA 39 wk 3 d 2928 5/  8 <1   [0] 30 [0]
20 M NA, TTN 28 wk 0 d 1144 6/  8 <1   [0] fi  <1 [  2] 25 [0] fi  32 [  2]
21* M NA, TTN 36 wk 6 d 2194 6/  9 <1   [0] 29 [0]
22 M NA, RDS 30 wk 0 d 1274 2/  5 <1   [0] 29 [0]
23 F NA, RDS 27 wk 4 d 954 1/  2 <1   [0] fi  <1 [  5] 30 [0] fi  34 [  5]
                 fi  <1 [8]               fi  35 [8]
24* M NA, RDS 36 wk 6 d 2412 6/  9 <1   [0] 36 [0]
25 M NA, TMI 31 wk 6 d 1840 2/  4 <1   [0] fi    1.2[2] 24 [0] fi  27 [  2]
                 fi  <1 [6]               fi  31 [6]
26 M NA, TMI 27 wk 4 d 1042 3/  6   3.0[0] fi  <1 [  5] 20 [0] fi  24 [  5]
                 fi  <1 [8]               fi  29 [8]
27 F NA, TMI 32 wk 5 d 1654 3/  7 <1   [0] fi  <1 [10] 22 [0] fi  29 [10]
28 M TTN 33 wk 5 d 2299 9/  9 <1   [0] fi  <1 [  3] 29 [0] fi  29 [  3]
29* F TTN 34 wk 2 d 1742 9/10 <1   [0] fi  <1 [  3] 22 [0] fi  29 [  3]
30 F TTN 36 wk 3 d 2494 8/  9 <1   [0] 38 [0]
31 M TTN 34 wk 4 d 2374 9/  9 <1   [0] fi  <1 [  2] 33 [0] fi  35 [  2]
32 M TTN, PPHN 35 wk 5 d 2300 9/  9 <1   [0] fi  <1 [  5] 31 [0] fi  31 [  5]
33 M RDS 34 wk 2 d 2000 8/  8 <1   [0] fi  <1 [  2] 17 [0] fi  27 [  2]
34 M RDS 31 wk 6 d 1599 9/10 <1   [0] 38 [0]
35 M TMI 36 wk 1 d 2862 8/  9 <1   [0] fi  <1 [10] 17 [0] fi  27 [10]
36 M EFE-like 37 wk 3 d 2402 8/10 <1   [0] fi  <1 [  6] 16 [0] fi  22 [  6]
37† M Anencephaly 36 wk 0 d 3000 8/  8 <1   [0] 25 [0]
38 M Latent FD 31 wk 6 d 1054 8/  8 <1   [0] fi  <1 [  2] 14 [0] fi  35 [  2]
d, day(s); EFE, endocardial fibroelastosis; F, female; FD, fetal distress; M, male; MAS, meconium aspiration
syndrome; MLC-I, myosin light chain I; LVSF, left ventricular shortening fraction; NA, neonatal asphyxia;
PPHN, persistent pulmonary hypertension of the newborn; RDS, respiratory distress syndrome; TMI,
transient myocardial ischemia of the newborn infant; TTN, transient tachypnea of the newborn; wk, week(s).
*TTTS, twin-to-twin transfusion syndrome:  patient numbers 21, 24 and 29.
†dead.
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not significantly different
from the normal group (Fig.
1).  On days 2 through 10,
MLC-I was measured again in
25 patients.  Regarding the
population breakdown by
disease, 12 patients had FD,
14 with NA, 9 with FD + NA,
5 with TTN, 4 with RDS, 1
with MAS, 2 with PPHN, 9
with TMI, 1 with EFE-like
disease, and 1 with latent FD
with decreased LVSF without
heart failure symptoms (over-
lap cases included).  One pa-
tient with TMI and another
with shock caused by anen-
cephaly died on day 0.  Of the
25 patients in whom MLC- I
re-measurements were per-
formed, 7 had elevated MLC-
I concentrations (1 with
MAS/PPHN and 6 with TMI).
All these 7 had FD and/or
NA.  Patients No.18 and 25
showed a biphasic pattern (a
rise followed by a fall) while in the other 5,
MLC-I concentrations were high on day 0 and
decreased below the detection limit on day 10.
In these 5 patients, changes of MLC-I could not
be measured (Table 1 and Fig.  2).
LVSF in normal neonates
The mean LVSF in normal neonates was 30.9 –
3.6% on day 0 and 31.2 –  3.0% on day 5, indi-
cating no significant difference between the 2
days.
LVSF in diseased neonates
In the present study, a fall in LVSF was noted in
18 neonates (18.9 –  5%).  On day 0, 9 of 18 with
FD, 11 of 21 with NA, 7 of 12 with FD + NA,
10 of 10 with TMI, 3 of 7 with RDS, 2 of 9 with
TTN, 1 of 1 with EFE-like disease, and 1 of 1
with latent FD with reduced LVSF without
heart failure symptoms, had reduced LVSF
(Table 1).  LVSF values in the NA, FD + NA
Fig. 2.  Nine cases with elevated MLC-I concentrations.  Numbers in
parentheses represent patient numbers from Table1.  Patient Nos. 18
and 25 showed a biphasic pattern of elevation followed by a fall in
MLC-I.  In the other patients, frequent measurements were not
performed.  MLC-I, myosin light chain I.
and TMI groups were significantly lower than
in normal neonates (P < 0.05).  However, there
were no significant differences between the
normal group and the FD, RDS and TTN groups
(Fig.  3).  Of the 18 patients with reduced
LVSF, one patient with TMI died on day 0, but
we were able to measure LVSF again in the
other 17 neonates on days 2 through 10.  The
data showed normalization in all but one neo-
nate with EFE-like disease.  In addition, of the
20 patients with normal LVSF on day 0, 8
showed normal LVSF values when this para-
meter was determined again at the time of re-
measurement of MLC-I (Table 1 ).
Correlation between MLC-I and LVSF
Since MLC-I was not elevated, except in 1 nor-
mal neonate and neonates with diseases other
than FD, NA, TMI and MAS/PPHN, it was
thought that the correlation of MLC-I and
LVSF was unlikely.  In 10 patients with TMI
and 9 with elevated MLC-I concentrations, the
M
LC
-I
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correlation between MLC-I and LVSF was ana-
lyzed using the peak MLC-I concentration ob-
tained during the period from days 0 to 10, and
the LVSF value measured on the day of peak
MLC-I concentration.  Although similar analy-
sis was conducted in patients with FD, NA and
FD + NA, no significant correlation was found
(TMI; r = 0.36, 9 patients with elevated MLC-I
concentrations; r = 0.36, FD; r = 0.073, NA; r =
0.055, FD + NA; r = 0.26).  In the other patients,
statistical analysis could not be performed due
to the small sample size.
Discussion
Assessment of heart function by echocardio-
graphy is very useful because it is practical and
simple.  Unlike echocardiography, which only
provides visual assessment of heart function,
quantitative determination of serum proteins
that originate from the myocardial muscles
provide information on myocardial damage and
such information is useful for management of
the circulatory system.  However, since creatine
phosphokinase (CK), aspartate aminotrans-
ferase (AST), myoglobin, which are intra-
cellular soluble proteins, readily move extra-
cellularly due to increased permeability of the
cell membrane during myocardial muscle dys-
function, these proteins are inappropriate in-
dexes of myocyte necrosis, although they are
highly sensitive in detecting ischemic-
associated myocardial disorders.  On the other
hand, MLC-I, a structural protein of myocardial
fiber, is very specific to myocardial muscle
necrosis because blood levels of this protein
become detectable only after necrosis of the
myocardium (Khaw et al.,1978; Trahern et al.,
1978).  In this regard, CK and CK-MB are also
non-specific for the myocardium in the neonate,
unlike in the adult (Cao et al., 1968; Omokhodion
et al., 1991; Primhak et al., 1985).
Concentrations under 1.0 ng/mL were con-
sidered normal, as shown in the study of
Murano and coworkers (1995) , who measured
Fig. 3.  LVSF in normal and different diseased groups.  LVSF is significantly lower in neonates with NA, FD
+ NA and TMI than in normal neonates. There is no significant difference in LVSF among the FD, RDS and
TTN groups and the normal group. FD, fetal distress; LVSF, left ventricular shortening fraction; NA, neonatal
asphyxia; NS, not significant; RDS, respiratory distress syndrome; TMI, transient myocardial ischemia of the
newborn infant; TTN, transient tachypnea of the newborn.
LV
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(%)
40
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MLC-I on day 0.  MLC-I concentrations under
1.0 ng/mL were considered normal in normal
neonates, irrespective of age.  Khaw and others
(1978) reported a crossreaction rate of not more
than 3% for myocardial MLC-I and skeletal
muscle MLC-I.  In our subject with a concen-
tration of 3.1 ng/mL, the Apgar score, LVSF
and troponin T (Katus et al., 1992) were 9
points, 27% and not more than 0.1 ng/mL, res-
pectively, suggesting a cross-reaction between
cardiac and skeletal muscles.
TMI is defined as a pathologic condition
associated with heart failure caused by transient
ischemia of the myocardium due to perinatal
hypoxia (Rowe, 1977).  Several pathophysio-
logical mechanisms have been proposed
(Kimura et al., 1982), including that of Rowe
and Hoffman (1972), who attributed TMI to
myocardial ischemia due to asphyxia and con-
current pulmonary vasoconstriction.  Morrow
and coworkers (1982) showed that a hypoxia-
induced rise in thromboxane A2 causes vaso-
constriction of pulmonary and coronary arteries
in TMI.  They also hypothesized the same
mechanism for the onset of PPHN and early
neonatal acute myocardial infarction (AMI).
On the other hand, PPHN is due to hypoxemia
and acidosis that develops soon after birth (Fox
and Duara, 1993).  With regard to the mecha-
nism for the onset, pulmonary vasoconstriction
is induced by thromboxane A2, prostaglandin
F2 a  and leukotrienes, and pulmonary vascular
developmental abnormalities due to chronic
hypoxemia (Morrow et al., 1982; Stenmark et
al., 1983).  In other words, PPHN can be viewed
as a severe form of pulmonary vasoconstriction
and TMI as coronary vasoconstriction, while
AMI is a form of TMI resulting from the ab-
sence of re-perfusion due to thrombosis and/or
embolism associated with coronary arterial
constriction.
Of our 38 patients, none with FD, NA, or
circulatory/respiratory diseases who did not
have associated TMI or PPHN showed elevated
MLC-I concentrations.  In addition, statistical
analysis demonstrated no significant differ-
ences in MLC-I, except for TMI, in comparison
with normal neonates.  These findings suggest
that MLC-I is highly specific for TMI, PPHN
and AMI.  With respect to the single patient
with shock caused by anencephaly who was
transferred from a nearby clinic while in a
shock condition, it appears that the shock was
induced by the concomitant hypoxemia.
MLC-I is thought to begin to increase at
about 4 h after the onset of AMI, reaching a
peak concentration at 2 to 4 days, followed by a
gradual decline, but remains elevated even at 10
days (Yazaki et al., 1980).  In those neonates
with unstable systemic conditions, such as
those with FD, NA or TMI, minimal handling is
an important component of overall manage-
ment.  In our patients investigated in the first
half of the study, MLC-I was remeasured at the
age of 10 days, as was recommended by Yazaki
and coworkers (1980).  However, in those with
abnormalities, MLC-I was below the detection
limit on day 10, unlike in adults.  Since frequent
measurements are very difficult in neonates
with poor systemic conditions, just as in adults,
MLC-I measurements were made as long as the
systemic condition was not affected (days 2, 3,
5 and 8).  Of the patients showing elevated
MLC-I concentrations, 2 showed a single-peak
change, in agreement with Yazaki and co-
workers (1980).  Furthermore, with regard to
the time of the onset of changes in MLC-I, the
MLC-I flow-out curves suggest that MLC-I can
be elevated both in fetal life and after delivery;
high concentrations were already found just
after delivery in some patients, while the
concentration was elevated on day 2 in another.
In older infants, LVSF does not depend on
age, body surface area, or heart rate but are
influenced by a variety of left ventricular loads.
Therefore, the accuracy of any assessment is
affected by abnormalities in left ventricular
wall motion.  Furthermore, in assessing LVSF,
special attention should be paid to the fact that
LVSF is elevated by an increased pre-load and a
reduced after-load (Johnson et al., 1976).  This
is more important in low birth weight infants,
who inevitably undergo therapeutic interven-
tion;  thus, it is substantially impossible to
establish normal values for these infants.  How-
ever, Murase and coworkers (1997) determined
the mean value of LVSF in very low birth
weight infants and demonstrated that this para-
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meter is more useful when determined serially.
LVSF values reported by these investigators
are, in general, similar to those measured in the
present study in normal neonates, suggesting
that LVSF serves as an index that is unlikely to
be affected by body weight and gestational age
in neonates born after 28 weeks of gestation.
We also examined the low LVSF values in
some of our patients, using as a reference the
mean values reported by Murase and coworkers
(1997).  As pointed out previously (Walther et
al., 1985; Gill and Weindling, 1993), LVSF was
significantly lower in the NA group than in nor-
mal neonates, with hypoxia as the likely cause.
Although no difference was noted in the FD
group, a significant difference was present in
the FD + NA group, and the number of patients
with low LVSF was smaller in the FD group
without NA at delivery.  These findings suggest
that LVSF depends mainly on hypoxia at deliv-
ery rather than in fetal life.  We also reported a
case with a low LVSF and very low birth weight
with no underlying disease and with a probable
diagnosis of latent fetal distress, based on the
rise in CK and AST concentrations at delivery.
As reported previously (Finley et al ., 1979;
Oh et al., 1985; Mitomori et al., 1989), a sig-
nificantly low LVSF was also noted in patients
with TMI alone.  Several TMI patients had ele-
vated MLC-I concentrations, indicating the
presence of some form of myocardial necrosis.
In these patients, we anticipated a delayed
recovery of LVSF, but we were unable to find
differences compared with patients with NA.
Although no differences were found in LVSF,
left ventricular posterior wall motion was
markedly decreased in all patients with TMI or
PPHN in the present study, as pointed out pre-
viously (Rowe and Hoffman, 1972; Mitomori et
al., 1989).  This is in agreement with earlier
studies demonstrating the relative frequency of
myocardial infarction in the left ventricular
posterior wall detected at autopsies of neonates
with AMI (Ravich and Rosenblatt, 1947;
Richart and Benirschke, 1959), supporting the
above mentioned hypothesis of Morrow and
others  (1982).  However, no similar finding
was noted in any other cases of asphyxia or
respiratory diseases, suggesting its usefulness
in differential diagnosis by echocardiography.
In addition, an index allowing quantitative
assessment of left ventricular posterior wall
motion would facilitate differential diagnosis.
In one patient with PPHN and elevated MLC-I
concentrations, the apparently normal LVSF
was attributed to increased pre-load associated
with moderate mitral insufficiency (Johnson et
al., 1976).  As for our patient with EFE-like
disease, heart failure was attributed to long-
term use in the mother of a high-dose of ritod-
rine throughout pregnancy (Katz and Seeds,
1989).
In adult patients with AMI, there is a signifi-
cant negative correlation between the left ven-
tricular ejection fraction and MLC-I during the
acute stage (Isobe et al., 1987).  We anticipated
a similar correlation between LVSF and MLC-I
in our patients with elevated MLC-I concen-
trations but unexpectedly failed to find such a
correlation.  Differences between adult and
neonates may be due to the following factors:  i)
Right ventricular pressure load and volume load
are accentuated by physiological pulmonary
hypertension during early neonatal life or by
pulmonary vasoconstriction inducing pulmo-
nary hypertension in hypoxic neonates, which
in turn adversely affects interventricular septal
wall motion and hence influences LVSF; ii)
Most patients with elevated MLC-I concen-
trations are in poor systemic condition neces-
sitating therapeutic intervention that can influ-
ence LVSF, such as intubation, oxygen therapy
and administration of catecholamines; also
different patients receive different treatments
that also invariably influence LVSF.
In conclusion, our study demonstrated that
elevated MLC-I concentrations occur specifi-
cally in a series of pathologic conditions, i.e.,
TMI, PPHN and AMI in neonates, suggesting
the potential usefulness of MLC-I for esti-
mating the onset and severity of myocardial
necrosis and as an index for the diagnosis and
management of circulatory disorders in these
conditions.  In addition, echocardiographically-
determined LVSF allowed estimation of the
affected sites, although the establishment of the
severity of this disorder remains elusive.
MLC-I and LVSF in neonates
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